Promoted Content Promoted Content

X

Find Approved Oncology Drugs in Clinical Development in AUSTRALIA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trabectedin

            Therapeutic Area: Oncology Product Name: Yondelis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 23, 2021

            Details:

            The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen".

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ripretinib

            Therapeutic Area: Oncology Product Name: Qinlock

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 06, 2020

            Details:

            Specialised Therapeutics Asia (STA) to make QINLOCK® (ripretinib) available to appropriate patients in Australia, New Zealand, Singapore, Malaysia and Brunei following exclusive distribution agreement.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Neratinib

            Therapeutic Area: Oncology Product Name: Nerlynx

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable